Parrish Capital’s GSK GSK Stock Holding History

Parrish Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.63M	Sell	29,588 -639	-2%	-$34.6K	1.46%	25
2025 Q4	$1.48M	Buy	+30,227	New	+$1.41M	1.34%	28

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Parrish Capital's GSK Position: Q1 2026 in Review

Parrish Capital reduced its GSK (GSK) stake by 2.1% in Q1 2026, selling an estimated $34.6K and leaving 29,588 shares worth $1.63M. The position accounts for 1.46% of the portfolio, ranked #25.

Parrish Capital first reported a position in GSK in Q4 2025 and has held it in 2 quarters since. 1,033 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Parrish Capital held 29,588 shares of GSK worth $1.63M as of Q1 2026.
Parrish Capital sold 639 GSK shares in Q1 2026, an estimated $34.6K.
GSK made up 1.46% of Parrish Capital's portfolio in Q1 2026, its #25 holding.
Parrish Capital first reported a position in GSK in Q4 2025 and has held it in 2 quarters since.
1,033 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Parrish Capital's 13F filing for Q1 2026, filed 28 Apr 2026.